Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy
Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering seq...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-11-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/23723556.2017.1378156 |
| _version_ | 1797677165653786624 |
|---|---|
| author | Samuel J. Taylor Wallace Y. Langdon |
| author_facet | Samuel J. Taylor Wallace Y. Langdon |
| author_sort | Samuel J. Taylor |
| collection | DOAJ |
| description | Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML). |
| first_indexed | 2024-03-11T22:41:07Z |
| format | Article |
| id | doaj.art-b9e4e534e08541699c88691d5d142cf1 |
| institution | Directory Open Access Journal |
| issn | 2372-3556 |
| language | English |
| last_indexed | 2024-03-11T22:41:07Z |
| publishDate | 2017-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Molecular & Cellular Oncology |
| spelling | doaj.art-b9e4e534e08541699c88691d5d142cf12023-09-22T09:10:58ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562017-11-014610.1080/23723556.2017.13781561378156Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapySamuel J. Taylor0Wallace Y. Langdon1School of Biomedical Sciences, University of Western AustraliaSchool of Biomedical Sciences, University of Western AustraliaMyelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).http://dx.doi.org/10.1080/23723556.2017.1378156flt3myelosuppressionquizartinibchemotherapyacute myeloid leukemiahematopoietic progenitors |
| spellingShingle | Samuel J. Taylor Wallace Y. Langdon Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy Molecular & Cellular Oncology flt3 myelosuppression quizartinib chemotherapy acute myeloid leukemia hematopoietic progenitors |
| title | Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy |
| title_full | Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy |
| title_fullStr | Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy |
| title_full_unstemmed | Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy |
| title_short | Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy |
| title_sort | hitting the snooze button inducing quiescence with the flt3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy |
| topic | flt3 myelosuppression quizartinib chemotherapy acute myeloid leukemia hematopoietic progenitors |
| url | http://dx.doi.org/10.1080/23723556.2017.1378156 |
| work_keys_str_mv | AT samueljtaylor hittingthesnoozebuttoninducingquiescencewiththeflt3inhibitorquizartinibprotectshematopoieticprogenitorsfromchemotherapy AT wallaceylangdon hittingthesnoozebuttoninducingquiescencewiththeflt3inhibitorquizartinibprotectshematopoieticprogenitorsfromchemotherapy |